Principal Investigator
Amy Brodtmann
Behavioural Neuroscience,
Florey Institute for Neuroscience and Mental Health,
Melbourne Brain Centre,
245 Burgundy Street
Heidelberg 3084, Australia.
agbrod@unimelb.edu.au
Summary
Country | Australia |
---|---|
Principal Investigator | Amy Brodtmann |
Contact person (email) | agbrod@unimelb.edu.au |
Key publication/reference | Brodtmann et al. Int J Stroke 2014;9:824-828 |
Years in which study conducted | 2014-2017 |
Sample | |
Size | 135 (intended) |
Population: Hospital/community | Hospital |
Selection: consecutive/random | ? |
Admit with previous stroke? | ? |
Admit with TIA? | ? |
Age range | 18+ |
Number of centres | 3 (Melbourne hospital stroke units) |
Control group: number, population, selection | N=40, from prior MRI studies and appropriate family members |
Assessment | |
Initial: Time and data collected/tests administered | Within 1m after stroke: MedHx, VRF, function, brief NΨ, IQCODE |
Detailed | 3m: function, IQCODE, brief NΨ, extended NΨ |
Subsequent (follow-ups) | 12m, 36m: same as 3m plus CDR, SASNOS |
Stroke-related data | NIHSS |
Functional tests/data | Modified Rankin scale, SASNOS |
Other medical tests/data | APO genotyping, general health, blood pressure, cholesterol |
Neuropsychological tests | Brief: test battery including NART and MoCA Extended: test battery covering 5 domains |
MRI scans, when and how many | 0, 3, 12, 36m |
PET scans | Amyloid in subgroup at 36m |
Psychiatric exams/diagnoses | Anxiety (GAD-7), CDR |
Intervention trialled? | No |
CT=computed tomography scan, MedHx=medical history, VRF=vascular risk factors (hypertension, diabetes, atrial fibrillation, obesity, smoking etc.), NΨ=neuropsychological, TIA=transient ischemic attack, m=month, y=year